NICE: Entyvio for Crohn’s Disease Needs More Supporting Evidence

NICE: Entyvio for Crohn’s Disease Needs More Supporting Evidence
The provider of national guidance and advice to improve health and social care in the United Kingdom, the National Institute for Health and Care Excellence (NICE), recently ruled against the approval of Entyvio (vedolizumab) as a treatment for Crohn’s Disease, a form of inflammatory bowel disease (IBD). NICE explained in a draft guidance that the Millennium Pharmaceuticals drug was

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *